Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Sponsors
Bayer
Conditions
Clinical Pharmacology
Phase 1
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
CompletedNCT04511637
Start: 2019-01-21End: 2019-04-12Updated: 2020-08-13
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
CompletedNCT04511611
Start: 2019-01-24End: 2019-05-13Updated: 2020-08-13